FEXOTA-40
Composition:Each tablet contains: Febuxostat IP 40 mg Excipients q.s.
| Composition | Composition:Each tablet contains: Febuxostat IP 40 mg Excipients q.s. |
| Packing | ALU ALU - 10*10 Tablets (ALU-ALU Packing) |
| MRP | ₹94 |
Product Overview
FEXOTA-40 is a modern, non-purine selective xanthine oxidase inhibitor containing 40mg of Febuxostat, designed for effective management of chronic hyperuricemia in gout. It offers clear clinical advantages over older therapies, providing dependable uric acid control without requiring routine dose adjustments for mild-to-moderate renal impairment. It stands as a premium, high-intent product for orthopaedic and internal medicine portfolios.
Indications
FEXOTA-40 is indicated for:
- Chronic Hyperuricemia: Long-term management of elevated blood uric acid levels in adult patients diagnosed with symptomatic gout.
- Gout Flare Prevention: Lowering systemic urate burden to reduce the frequency and severity of painful joint inflammation.
- Allopurinol Intolerance: Serving as an effective, first-line alternative for patients who show poor clinical response or hypersensitivity to allopurinol.
Dosage & Administration
Adults: The recommended initial dose is 1 tablet (40 mg) taken once daily, with or without food. If serum uric acid levels remain above 6 mg/dL after 2 to 4 weeks of continuous therapy, the dose may be escalated to 80 mg once daily under medical supervision.
Adverse Effects
Commonly reported clinical side effects include:
- Acute gout flares (frequently observed during early phases of therapy as urate stores shift)
- Liver function test abnormalities (elevated transaminases)
- Nausea or localized diarrhea
- Arthralgia (joint discomfort) and mild skin rashes
View Complete Medical Information
Contraindications
Contraindicated in patients with known hypersensitivity to febuxostat or any formulation excipients. Do not use in patients undergoing concurrent treatment with purine analogues such as azathioprine or mercaptopurine.
Warnings & Precautions
Not recommended for asymptomatic hyperuricemia. Monitor for signs of cardiovascular events and track hepatic enzyme levels before and periodically during therapy. Concurrent prophylactic therapy with an NSAID or colchicine is highly recommended when initiating treatment to manage acute gout flares.
Drug Interactions
Inhibition of xanthine oxidase by febuxostat can significantly increase the plasma concentrations of azathioprine, mercaptopurine, and theophylline, potentially leading to severe hematological toxicities.
Storage Instructions
Store below 30°C in a dry place. Keep the container tightly sealed and protected from light.
Request This Product
- WHO-GMP Certified Formulations
- Monopoly Rights Available
- Get bulk pricing & MOQ
+91 9689237122 · replies within hours
Related Products
More products in the ORTHO therapeutic category
LINSEED GEL
Diclofenac Diethylamine BP 2.32% w/w Eq To Diclofenac Sodium 2% w/w Linseed Oil BP 3% w/w Methyl Salicylate IP 10 %w/w Menthol IP 5 % w/wBenzyl alcohol IP (preservative) 1% w/w Gel Base q.s.
LAMINATED TUBE - 30 GM
ROSICIAN TAB [30*1]
Each FIim tablet contains : Boswellia Serrata Extract (65%) 307.5 mg Devils claw extract (20%) 100 mg Rose hip extract 275 mg
WHITE HDPE BOTTLE WITH CARTON - 30*1
ETOCIAN MR
Composition:Each tablet contains: Etoricoxib IP 60 mg Thiocolchicoside IP 8 mg Excipients q.s.
ALU ALU - 10*10 Tablets (ALU-ALU Packing)
Interested in this product?
Contact our team to discuss PCD franchise, bulk orders, or contract manufacturing for your market.